An overview on natural cholinesterase inhibitors - a multi-targeted drug class - and their mass production

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 836-842

  Orhan, I Erdogan ^a,b   Orhan, G ^c   Gurkas, E ^c  

^a GAZI UNIVERSITY   (Turkey)

^b EASTERN MEDITERRANEAN UNIVERSITY   (Turkey)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cholinesterase inhibition; Galanthamine; Huperzine a; In vitro plant culture; Organic synthesis

Indexed keywords

12 FLUOROHUPERZINE A; 7 ETHYLHUPERZINE A; 9 DEHYDROGALANTHAMINIUM BROMIDE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; PHENSERINE; PHYSOSTIGMINE; PHYSOSTIGMINE SALICYLATE; PLACEBO; SYNAPTON; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SYNTHESIS; HUMAN; HUPERZIA; HYPERTENSION; IN VITRO STUDY; UNSPECIFIED SIDE EFFECT;

ALKALOIDS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; GALANTAMINE; HUMANS; HUPERZIA; LILIACEAE; SESQUITERPENES;

EID: 79960999435     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711796575434     Document Type: Article

References (89)

1. Cokugras, N.A. Butyrylcholinesterase: Structure and physiological importance. Turk. J. Biochem., 2003, 28, 54-61.
2. Martorana, A.; Esposito, Z.; Koch, G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci. Ther., 2010, 16, 235-245.
3. Nieoullon, A. Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences. Psychol. Neuropsychiatr. Vieil., 2010, 8, 123-131.
4. Aquilonius, S.M.; Hartvig, P. Clinical pharmacokinetics of cholinesterase inhibitors. Clin. Pharmacokinet., 1986, 11, 236-249.
5. Henze, T. Therapy of myasthenia gravis with cholinesterase inhibitors - Principles and pharmacologic monitoring. Fortschr. Neurol. Psychiatr., 1996, 64, 110-121.
6. Millard, C.B.; Broomfield, C.A. Anticholinesterases: medical applications of neurochemical principles. J. Neurochem., 1995, 64, 1909-1918.
7. Hoyng, P.F.; van Beek, L.M. Pharmacological therapy for glaucoma: a review. Drugs, 2000, 59, 411-434.
8. Giacobini, E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol. Res., 2004, 50, 433-440.
9. Larner, A.J. Cholinesterase inhibitors: beyond Alzheimer's disease. Expert Rev. Neurother., 2010, 10, 1699-1705.
10. Turan, A.; Karamanlioglu, B.; Memis, D.; Kaya, G.; Pamukçu, Z. Intravenous regional anesthesia using prilocaine and neostigmine. Anesth. Analg., 2002, 95, 1419-1422.
11. Kolbezen, M.J.; Metcalf, R.L.; Fukuto, T.R. Insecticide structure and activity, insecticidal activity of carbamate cholinesterase inhibitors. J. Agric. Food Chem., 1954, 2, 864-870.
12. Kumar, A.; Doan, H.; Barnes, M.; Chapman, J.C.; Kookana, R.S. Response and recovery of acetylcholinesterase activity in freshwater shrimp, Paratya australiensis (Decapoda: Atyidae) exposed to selected anti-cholinesterase insecticides. Ecotoxicol. Environ. Saf., 2010, 73, 1503-1510.
13. Pavlov, V.; Xiao, Y.; Willner, I. Inhibition of the acetycholinesterase- stimulated growth of Au nanoparticles: nanotechnology- based sensing of nerve gases. Nano Lett., 2005, 5, 649-53.
14. Lockridge, O.; Mottershow-Jackson, N.; Eckerson, H.W.; La Du, B.N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmac. Exp., 1980, 215, 1-8.
15. Traub, S.J.; Nelson, H. Physostigmine as a treatment for gammahydroxybutyrate toxicity: a review. J. Toxicol.Clin. Toxicol., 2002, 40, 781-787.
16. Prostran, M.; Varagić, V.M.; Todorovi ć, Z.; Jezdimirovi ć, M. The effects of physostigmine, L-arginine and NG-nitro-L-arginine methyl ester (L-NAME) on the mean arterial pressure of the rat. J. Basic Clin. Physiol. Pharmacol., 1994, 5, 151-166.
17. Lindén, C.; Alm, A. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch. Ophthalmol., 1997, 115, 857-861.
18. Standridge, J.B. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin. Ther., 2004, 26, 615-630.
19. Bickel, U.; Thomsen, T.; Fischer, J.P.; Weber, W.; Kewitz, K. Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacol., 1991, 30, 447-454.
20. Orhan, G.; Orhan, I., Sener, B. Recent developments in natural and synthetic drug research for Alzheimer's Disease. Lett. Drug Des. Disc., 2006, 3, 268-274.
21. Geerts, H.; Guillaumat, P.O.; Grantham, C.; Bode, W.; Anciaux, K.; Sachak, S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res., 2005, 1033, 186-193.
22. Orhan, I.; Sener, B. Bioactivity-directed fractionation of alkaloids from some Amaryllidaceae plants and their anticholinesterase inhibitory activity. Chem. Nat. Compds., 2003, 39, 383-386.
23. Mu, H.M.; Wang, R.; Li, X.D.; Jiang, Y.M.; Peng, F.; Xia, B. Alkaloid accumulation in different parts and ages of Lycoris chinensis. Z. Naturforsch. C, 2010, 65, 458-462.
24. Heinrich, M. Galanthamine from Galanthus and other Amaryllidaceae- chemistry and biology based on traditional use. Alkaloids Chem. Biol., 2010, 68, 157-165.
25. Thomsen, T.; Kewitz, H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci., 1990, 46, 1553-1558.
26. Coyle, J.; Kershaw, P. Galanthamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease. Biol. Psychiatry, 2001, 49, 289-299.
27. Woodruff-Pak, D.S.; Lander, C.; Geerts, H. Nicotinic cholinergic modulation: Galanthamine as a prototype. CNS Drug Rev., 2002, 8, 405-426.
28. Bartolucci, C.; Perola, E.; Pilger, C.; Fels, G.; Lamba, D. Threedimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti-Alzheimer drugs. Proteins, 2001, 42, 182-191.
29. Raskind, M.A.; Peskind, E.R.; Wessel, T.; Yuan, W and the galantamine USA-1 Study Group. Galanthamine in AD: A 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology, 2000, 54, 2261-2268.
30. Wilcock, G.K.; Lilienfeld, F.; Gaens, E. and for the galanthamine International-l Study Group. Efficacy and safety of galanthamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial. BMJ, 2000, 32, 1445-1449.
31. Litvinenko, I.V.; Odinak, M.M.; Mogil'naya, V.I.; Emelin, A.Y. Efficacy and safety of galanthamine (Reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci. Behav. Physiol., 2008, 38, 937-945.
32. Ghaemi, S.N., Gilmer, W.S., Dunn, R.T.; Hanlon, R.E.; Kemp, D.E.; Bauer, A.D.; Chriki, L.; Filkowski, M.M.; Harvey, P.D. A double-blind, placebo-controlled pilot study of galanthamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J. Clin. Psychopharmacol., 2009, 29, 291-295.
33. Rockwood, K.; Fay, S.; Gorman, M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galanthamine for Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2010, 25, 191-201.
34. Suh, W.H.; Suslick, K.S.; Suh, Y.H. Therapeutic agents for Alzheimer's disease. Curr. Med. Chem. - CNS Agents, 2005, 5, 259-269.
35. Kametani, T.; Yamaki, K.; Yagi, H.; Fukumoto, K. Studies on the synthesis of heterocyclic compounds. CCCXV. Modified total synthesis of (plus or minus)-galanthamine through phenol oxidation. J. Chem. Soc. Perkin 1, 1969, 18, 2602-2605.
36. Pelish, H.E.; Westwood, N.J.; Feng, Y.; Kirchhausen, T.; Shair, M.D. Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product. J. Am. Chem. Soc., 2001, 123, 6740-6741.
37. Kodama, S.; Hamashima, Y.; Nishide, K.; Node, M. Total synthesis of (-)-galanthamine by remote asymmetric induction. Angew. Chem. Int. Ed. Engl., 2004, 43, 2659-2661.
38. Marco-Contelles, J.; Rodríguez, C.; García, A.G. Chemical synthesis of galanthamine, an acetylcholinesterase inhibitor for treatment of Alzheimer's disease. Exp. Op. Ther. Pat., 2005, 15, 575-587.
39. Hu, X.D.; Tu, Y.Q.; Zhang, E.; Gao, S.; Wang, S.; Wang, A.; Fan, C.A.; Wang, M. Total synthesis of (+/-)-galanthamine. Org. Lett., 2006, 8, 1823-1825.
40. Tanimoto, H.; Kato, T.; Chida, N. Total synthesis of (+)- galanthamine starting from D-glucose. Tetrahedron Lett., 2007, 48, 6267-6270.
41. Chang, J.H.; Kang, H.U.; Jung, I.H.; Cho, C.G. Total synthesis of (+/-)-galanthamine via a C3-selective Stille coupling and IMDA cycloaddition cascade of 3,5-dibromo-2-pyrone. Org. Lett., 2010, 12, 2016-2018.
42. Czollner, L.; Frantsits, W.; Kiienburg, B.; Hedenig, I.; Frohlich, J.; Jordis, U.S. Kilogram-synthesis of the anti-Alzheimer drug (-)- galanthamine. Tetrahedron Lett., 39, 2087-2088.
43. Han, S.Y.; Mayer, S.C.; Schweiger, E.J.; Davis, B.M.; Joulleé, M.M. Synthesis and biological activity of galanthamine derivatives as acetylcholinesterase (AChE) inhibitors. Bioorg. Med. Chem. Lett., 1991, 1, 579-580.
44. Mary, A.; Renko, D.Z.; Guillou, C.; Thal, C. Potent acetylcholinesterase inhibitors: Design, synthesis and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg. Med. Chem., 1998, 6, 1835-1850.
45. Guillou, C.; Mary, A.; Renko, D.Z.; Gras, E.; Thal, C. Potent acetylcholinesterase inhibitors: Design, synthesis and structure-activity relationships of alkylene-linked bis-galanthamine and galanthamine- galanthaminium salts. Bioorg. Med. Chem., 2000, 10, 637-639.
46. Berkov, S.; Codina, C.; Viladomat, F.; Bastida, J. N-alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. Bioorg. Med. Chem. Lett., 2008, 18, 2263-2266.
47. Jia, P.; Sheng, R.; Zhang, J.; Fang, L.; He, Q.; Yang, B.; Hu, Y. Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors. Eur. J. Med. Chem., 2009, 44, 772-784.
48. Herlem, D.; Martin, M.T.; Thal, C.; Guillou, C. Synthesis and structure-activity relationships of open D-ring galanthamine analogues. Bioorg. Med. Chem. Lett., 2003, 13, 2389-2391.
49. Lamirault, L.; Guillou, C.; Thal, C.; Simon, H. (-)-9- Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats. Neurobiol. Learn. Mem., 2003, 8, 113-122.
50. Berkov, S.; Georgieva, L.; Kondakova, V.; Atanassov, A.; Viladomat, F.; Bastida, J.; Codina, C. Plant sources of galanthamine: Phytochemical and biotechnological aspects. Biotechnol. Biotechnol., 2009, 23, 1170-1176.
51. Pavlov, A.; Berkov, S.; Courot, E.; Gocheva, T.; Tuneva, D.; Pandova, B.; Georgiev, M.; Georgiev, V.; Yanev, S.; Burrus, M.; Ilieva, M. Galanthamine production by Leucojum aestivum in vitro systems. Process Biochem., 2007, 42, 734-739.
52. Diop, M.F.; Hehn, A.; Ptak, A.; Chretien, F.; Doerper, S.; Gontier, E.; Bourgaud, F.; Henry, M.; Chapleur, Y.; Laurain-Mattar, D. Hairy root and tissue cultures of Leucojum aestivum L.- relationships to galanthamine content. Phytochem. Rev., 2007, 6, 137-141.
53. Palazon, J.; Cusido, R.M.; Gonzalio, J.; Bonfill, M.; Morales, C.; Pinnol, T. Relation between the amount of rolC gene product and indole alkaloid accumulation in Catharanthus roseus transformed root cultures. J. Plant Physiol., 1998, 153, 712-718.
54. Georgiev, V.; Berkov, S.; Georgiev, M.; Burrus, M.; Codina, C.; Bastida, J.; Ilieva, M.; Pavlov, A. Optimized nutrient medium for galanthamine production in Leucojum aestivum L. in vitro shoot system. Z. Naturforsch. C, 2009, 64, 219-224.
55. Ptak, A.; El Tahchy, A.; Dupire, F.; Boisbrun, M.; Henry, M.; Chapleur, Y.; Moś, M.; Laurain-Mattar, D. LC-MS and GC-MS for the screening of alkaloids in natural and in vitro extracts of Leucojum aestivum. J. Nat. Prod., 2009, 72, 142-147.
56. El Tahchy, A.; Boisbrun, M.; Ptak, A.; Dupire, F.; Chrétien, F.; Henry, M.; Chapleur, Y.; Laurain-Mattar, D. New method for the study of Amaryllidaceae alkaloid biosynthesis using biotransformation of deuterium-labeled precursor in tissue cultures. Acta Biochim. Pol., 2010, 57, 75-82.
57. Ivanov, I.; Georgiev, V.; Georgiev, M.; Ilieva, M.; Pavlov, A. Galanthamine and related alkaloids production by Leucojum aestivum L. shoot culture using a temporary immersion technology. Appl. Biochem. Biotechnol. 163, 268-277.
58. Colque, R.; Viladomat, F.; Bastida, J.; Codina, C. Improved production of galanthamine and related alkaloids by methyl jasmonate in Narcissus confusus shoot clumps. Planta Med., 2004, 70, 1180-1188.
59. Bergonon, S.; Codina, C.; Bastida, J.; Viladomat, F.; Mele, E. Galanthamine production in "shoot-clump" cultures of Narcissus confuses in liquid-shake medium. Plant Cell Tiss. Org. Cult., 1996, 45, 191-199.
60. Santos, J.; Santos, I.; Salema, R. In vitro production of bulbs of Narcissus bulbocodium flowering in the first season of growth. Sci. Horticult., 1998, 76, 205-217.
61. Selles, M.; Viladomat, F.; Bastida, J.; Codina, C. Callus induction, somatic embryogenesis and organogenesis in Narcissus confusus: Correlation between the state of differentiation and the content of galanthamine and related alkaloids. Plant Cell Rep., 1999, 18, 646-651.
62. Mu, H.M.; Wang, R.; Li, X.D.; Jiang, Y.M.; Wang, C.Y.; Quan, J.P.; Peng, F.; Xia, B. Effect of abiotic and biotic elicitors on growth and alkaloid accumulation of Lycoris chinensis seedlings. Z. Naturforsch. C, 2009, 64, 541-550.
63. Berkov, S.; Pavlov, A.; Georgiev, V.; Weber, J.; Bley, T.; Viladomat, F.; Bastida, J.; Codina, C. Changes in apolar metabolites during in vitro organogenesis of Pancratium maritimum. Plant Phsiol. Biochem., 2010, 48, 827-835.
64. Guo, B.; Xu, L.; Wei, Y.; Liu, C. Research advances of Huperzia serrata (Thunb.) Trev. J. Chin. Mat. Med., 2009, 34, 2018-2023.
65. Ma, X.; Tan, C.; Zhu, D.; Gang, D.R.; Xiao, P. Huperzine A from Huperzia species -An ethnopharmacological review. J. Ethnopharmacol., 2007, 113, 15-34.
66. Zhang, H.Y.; Tang, X.C. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol. Sci., 2006, 27, 619-625.
67. Tang, X.C. Huperzine A shuangyiping: a promising drug for Alzheimer's disease. Zhongguo Yao Li Xue Bao, 1996, 17, 481-484.
68. Xu, S.S.; Cai, Z.Y.; Qu, Z.W.; Yang, R.M.; Cai, Y.L.; Wang, G.Q.; Su, X.Q.; Zhong, X.S.; Cheng, R.Y.; Xu,W.A.; Li, J.X.; Feng, B. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao, 1999, 20, 486-490.
69. Zhang, Z.; Wang, X.; Chen, Q.; Shu, L.; Wang, J.; Shan, G. Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi, 2002, 82, 941-944.
70. http://www.clinicaltrials.gov/show/NCT00083590. (Access date: 01.February.2011)
71. Bai, D. Development of huperzine A and B for treatment of Alzheimer's disease. Pure Appl. Chem., 2007, 79, 469-479.
72. Qian, L.; Ji, R. A total synthesis of (±)-huperzine A. Tetrahedron Lett., 1989, 30, 2089-2090.
73. Kozikowski, A.P.; Tückmantel, W. Chemistry, pharmacology, and clinical efficacy of the Chinese nootropic agent huperzine A. Acc. Chem. Res., 1999, 32, 641-650.
74. Foricher, Y.; Mann, J. A convergent approach to huperzine A and analogues. Tetrahedron Lett., 2000, 41, 2007-2009.
75. Lucey, C.; Kelly, S.A.; Mann, J. A concise and convergent (formal) total synthesis of huperzine A. Org. Biomol. Chem., 2007, 5, 301-306.
76. Tang, X.C.; Kindel, G.H.; Koziowski, A.P.; Hanin, I. Comparison of the effects natural and synthetic huperzine A on rat brain cholinergic function in vitro and in vivo. J. Ethnopharmacol., 1994, 44, 147-155.
77. Zhang, H.Y.; Liang, Y.Q.; Tang, X.C.; He, X.C.; Bai, D.L. Stereoselectivites of enantiomers of huperzine A in protection against β- amyloid25-35-induced injury in PC12 cells and cholinesterase inhibition in mice. Neurosci. Lett., 2002, 317, 143-146.
78. Tumiatti, V.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Milelli, A.; Matera, R.; Melchiorre, C. Progress in acetylcholinesterase inhibitors for Alzheimer's disease: An update. Exp. Op. Ther. Pat., 2008, 18, 387-401.
79. Kaneko, S.; Nakajima, N.; Shikano, M.; Katoh, T.; Terashima, S. Synthetic studies of huperzine A and its fluorinated analogues. 2. Synthesis and acetylcholinesterase inhibitory activity of novel fluorinated huperzine A analogues. Tetrahedron, 1998, 54, 5485-5506.
80. Zeng, F.; Jiang, H.; Tang, X.; Chen, K.; Ji, R. Synthesis and acetylcholinesterase inhibitory activity of (±)-14-fluorohuperzine A. Bioorg. Med. Chem. Lett., 1998, 8, 1661-1664.
81. Camps, P.; Contreras, J.; El Achab, R.; Morral, J.; Munoz-Torrero, D.; Font-Bardia, M.; Solans, X.; Badia, A.; Vivas, N.M. New syntheses of rac-huperzine A and its rac-7-ethyl derivative. Evaluation of several huperzine A analogues as acetylcholinesterase inhibitors. Tetrahedron, 2000, 56, 4541-4553.
82. Campiani, G.; Kozikowski, A.P.; Wang, S.; Ming, L.; Nacci, V.; Saxena, A.; Doctor, B.P. Synthesis and anticholinesterase activity of huperzine A analogues containing phenol and catechol replacements for the pyridone ring. Bioorg. Med. Chem. Lett., 1998, 8, 1413-1418.
83. Högenauer, K.; Baumann, K.; Enz, A.; Mulzer, J. Synthesis and acetylcholinesterase inhibition of 5-desaminohuperzine A derivatives. Bioorg. Med. Chem. Lett., 2001, 11, 2627-2630.
84. Ma, X.Q.; Jiang, S.H.; Zhu, D.Y. Alkaloid patterns in Huperzia and some related genera of Lycopodiaceae sensu lato occurring in China and their contribution to classification. Biochem. Systemat. Ecol., 1998, 26, 723-728.
85. Freeberg, J.A.; Wetmore, R.H. Gametophytes of Lycopodium as grown in vitro. Phytomorphol., 1957, 7, 204-217.
86. Freeberg, J.A.; Wetmore, R.H. The Lycopsida - A study in development. Phytomorphol., 1967, 17, 78-91.
87. Szypuła, W.; Pietrosiuk, A.; Suchocki, P.; Olszowska, O.; Furmanowa, M.; Kazimierska, O. Somatic embryogenesis and in vitro culture of Huperzia selago shoots as a potential source of huperzine A. Plant Sci., 2005, 168, 1443-1452.
88. Ma, X.; Gang, D.R. In vitro production of huperzine A, a promising drug candidate for Alzheimer's disease. Phytochemistry, 2008, 69, 2022-2028.
89. Zhu, D.; Wang, J.; Zheng, Q.; Zhang, Z.; Yan, R. A novel endophytic huperzine A-producing fungus, Shiraia sp. Slf14, isolated from Huperzia serrata. J. Appl. Microbiol., 2010, 109, 1469-1478.